DDInter1060 DDInter1376
Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Levonordefrin {u} (Compound) resembles {v} (Compound) Levodopa
Levonordefrin {u} (Compound) resembles {v} (Compound) Droxidopa
Levonordefrin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isoprenaline
Levonordefrin {u} (Compound) binds {v} (Gene) SLC6A2
Levonordefrin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methylene blue
Levonordefrin {u} may lead to a major life threatening interaction when taken with {v} Doxepin
Levonordefrin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenylpropanolamine
Levonordefrin (Compound) resembles Levodopa (Compound)
Levonordefrin (Compound) resembles Droxidopa (Compound)
Levonordefrin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Levonordefrin (Compound) binds SLC6A2 (Gene)
Levonordefrin may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Levonordefrin may lead to a major life threatening interaction when taken with Doxepin
Levonordefrin (Compound) resembles Phenylpropanolamine (Compound) and Levonordefrin may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine